Literature DB >> 8103891

Brucella melitensis Rev-1 vaccine as a cause of human brucellosis.

J M Blasco, R Díaz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8103891     DOI： 10.1016/0140-6736(93)91571-3

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  33 in total

1.  Cloning of a Brucella melitensis group 3 antigen gene encoding Omp28, a protein recognized by the humoral immune response during human brucellosis.

Authors:  L E Lindler; T L Hadfield; B D Tall; N J Snellings; F A Rubin; L L Van De Verg; D Hoover; R L Warren
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Stability of poly(epsilon-caprolactone) microparticles containing Brucella ovis antigens as a vaccine delivery system against brucellosis.

Authors:  Maite Estevan; Carlos Gamazo; Fernando Martínez-Galan; Juan M Irache
Journal:  AAPS PharmSciTech       Date:  2008-10-16       Impact factor: 3.246

3.  Vaccination with the recombinant Brucella outer membrane protein 31 or a derived 27-amino-acid synthetic peptide elicits a CD4+ T helper 1 response that protects against Brucella melitensis infection.

Authors:  Juliana Cassataro; Silvia M Estein; Karina A Pasquevich; Carlos A Velikovsky; Silvia de la Barrera; Raúl Bowden; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

4.  A DNA vaccine coding for the Brucella outer membrane protein 31 confers protection against B. melitensis and B. ovis infection by eliciting a specific cytotoxic response.

Authors:  Juliana Cassataro; Carlos A Velikovsky; Silvia de la Barrera; Silvia M Estein; Laura Bruno; Raúl Bowden; Karina A Pasquevich; Carlos A Fossati; Guillermo H Giambartolomei
Journal:  Infect Immun       Date:  2005-10       Impact factor: 3.441

5.  Protective live oral brucellosis vaccines stimulate Th1 and th17 cell responses.

Authors:  Beata Clapp; Jerod A Skyberg; Xinghong Yang; Theresa Thornburg; Nancy Walters; David W Pascual
Journal:  Infect Immun       Date:  2011-07-18       Impact factor: 3.441

6.  Comparison of protective efficacy of subcutaneous versus intranasal immunization of mice with a Brucella melitensis lipopolysaccharide subunit vaccine.

Authors:  Apurba K Bhattacharjee; Mina J Izadjoo; Wendell D Zollinger; Mikeljon P Nikolich; David L Hoover
Journal:  Infect Immun       Date:  2006-10       Impact factor: 3.441

7.  Partial protection against Brucella infection in mice by immunization with nonpathogenic alphaproteobacteria.

Authors:  M Victoria Delpino; Silvia M Estein; Carlos A Fossati; Pablo C Baldi
Journal:  Clin Vaccine Immunol       Date:  2007-08-22

8.  Protective immunity to Brucella ovis in BALB/c mice following recovery from primary infection or immunization with subcellular vaccines.

Authors:  M P Jiménez de Bagüés; P H Elzer; J M Blasco; C M Marín; C Gamazo; A J Winter
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.

Authors:  M P Jiménez de Bagüés; P H Elzer; S M Jones; J M Blasco; F M Enright; G G Schurig; A J Winter
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.